FT819 for B-cell Mediated Autoimmune Diseases
Fate is currently enrolling patients in a Phase 1 clinical trial for FT819, an iPSC-derived CAR T-call treatment in development for patients with moderate to severe active systemic lupus erythematosus (SLE), antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc). To learn more about FT819, visit our Product Candidates page.
To find out more about the trial and eligibility, visit clinicaltrials.gov.
FT825 for Advanced Solid Tumors
Fate is currently enrolling patients in a Phase 1 clinical trial for FT825, an iPSC-derived CAR T-call treatment in development for patients with solid tumors. To learn more about FT825, visit our Product Candidates page.
To find out more about the trial and eligibility, visit clinicaltrials.gov.
FT836 for Solid Tumors
Not yet enrolling.
If you are a healthcare provider interested in learning more about one of our clinical trials, please email clinicaltrials@fatetherapeutics.com